Evidence map›Paper›PMID 31422082›Full record

ArticleMolecular metabolism2019

Double bond configuration of palmitoleate is critical for atheroprotection.

Ismail Cimen, Zehra Yildirim, Asli Ekin Dogan, Asli Dilber Yildirim, Ozlem Tufanli, Umut Inci Onat, UyenThao Nguyen, Steven M Watkins, Christian Weber, Ebru Erbay

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Ismail CimenInstitute for Cardiovascular Prevention, LMU Munich, German Cardiovascular Research Centre (DZHK), Partner Site Munich Heart Alliance Munich, 80336, Germany.
Zehra YildirimDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey; National Nanotechnology Center, Bilkent University, Ankara, 06800, Turkey; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Asli Ekin DoganDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey; National Nanotechnology Center, Bilkent University, Ankara, 06800, Turkey; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Asli Dilber YildirimDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey; National Nanotechnology Center, Bilkent University, Ankara, 06800, Turkey; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Ozlem TufanliNew York University, Lagone Medical Center, New York, NY 10016, USA.
Umut Inci OnatDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey; National Nanotechnology Center, Bilkent University, Ankara, 06800, Turkey.
UyenThao NguyenMetabolon, Morrisville, NC, 27560, USA.
Steven M WatkinsVerso Biosciences, San Francisco, CA, 94124, USA.
Christian WeberInstitute for Cardiovascular Prevention, LMU Munich, German Cardiovascular Research Centre (DZHK), Partner Site Munich Heart Alliance Munich, 80336, Germany; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
Ebru ErbayDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey; National Nanotechnology Center, Bilkent University, Ankara, 06800, Turkey; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. Electronic address: ebru.erbay@cshs.org.
Bilkent University · TRCedars-Sinai Medical Center · USCedars-Sinai Smidt Heart Institute · USGerman Centre for Cardiovascular Research · DELudwig-Maximilians-Universität München · DEMetabolon (United States) · USNYU Langone Health · US

Funding

European Research Council 692511
6 · The paper itself

Abstract

objectiveSaturated and trans fat consumption is associated with increased cardiovascular disease (CVD) risk. Current dietary guidelines recommend low fat and significantly reduced trans fat intake. Full fat dairy can worsen dyslipidemia, but recent epidemiological studies show full-fat dairy consumption may reduce diabetes and CVD risk. This dairy paradox prompted a reassessment of the dietary guidelines. The beneficial metabolic effects in dairy have been claimed for a ruminant-derived, trans fatty acid, trans-C16:1n-7 or trans-palmitoleate (trans-PAO). A close relative, cis-PAO, is produced by de novo lipogenesis and mediates inter-organ crosstalk, improving insulin-sensitivity and alleviating atherosclerosis in mice. These findings suggest trans-PAO may be a useful substitute for full fat dairy, but a metabolic function for trans-PAO has not been shown to date.

methodsUsing lipidomics, we directly investigated trans-PAO's impact on plasma and tissue lipid profiles in a hypercholesterolemic atherosclerosis mouse model. Furthermore, we investigated trans-PAO's impact on hyperlipidemia-induced inflammation and atherosclerosis progression in these mice.

resultsOral trans-PAO supplementation led to significant incorporation of trans-PAO into major lipid species in plasma and tissues. Unlike cis-PAO, however, trans-PAO did not prevent organelle stress and inflammation in macrophages or atherosclerosis progression in mice.

conclusionsA significant, inverse correlation between circulating trans-PAO levels and diabetes incidence and cardiovascular mortality has been reported. Our findings show that trans-PAO can incorporate efficiently into the same pools that its cis counterpart is known to incorporate into. However, we found trans-PAO's anti-inflammatory and anti-atherosclerotic effects are muted due to its different structure from cis-PAO.

Indexed as

AnimalsAtherosclerosisCells, CulturedFatty Acids, MonounsaturatedMaleMiceMice, KnockoutFatty Acids, Monounsaturatedpalmitoleic acidAtherosclerosisInflammasomeLipid-induced inflammationLipokinesOrganelle stressPalmitoleateRuminant trans-fatty acids

Identifiers

PMID31422082
PMCPMC6822256
OpenAlexW2966496040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.